NOVADIP INNOVATIVE CELL THERAPIES Trademark

Trademark Overview

On Thursday, November 19, 2015, a trademark application was filed for NOVADIP INNOVATIVE CELL THERAPIES with the United States Patent and Trademark Office. The USPTO has given the NOVADIP INNOVATIVE CELL THERAPIES trademark a serial number of 79180801. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, March 29, 2024. This trademark is owned by NOVADIP BIOSCIENCES. The NOVADIP INNOVATIVE CELL THERAPIES trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific and technological services, namely, scientific and medical research and product development in the field of treatment, reconstruction, growth, renewal and repair of tissues and organs; medical research and consulting related thereto in the field of diagnostics and cell therapy and product research and development in the field of medical and surgical instruments

General Information

Serial Number79180801
Word MarkNOVADIP INNOVATIVE CELL THERAPIES
Filing DateThursday, November 19, 2015
Status709 - CANCELLED - SECTION 71
Status DateFriday, March 29, 2024
Registration Number5283021
Registration DateTuesday, September 12, 2017
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, June 27, 2017

Trademark Statements

Description of MarkThe mark consists of the wording "NOVADIP" in stylized teal font above the wording "INNOVATIVE CELL THERAPIES" in stylized light teal font. To the left is a circular design composed of numerous dots of varying sizes in the colors dark blue, blue and light blue. The foregoing elements appear on a white background.
Pseudo MarkNOVA DIP INNOVATIVE CELL THERAPIES
Indication of Colors claimedThe color(s) dark blue, blue, light blue, teal, light teal and white is/are claimed as a feature of the mark.
Translation of Words in MarkThe wording "NOVADIP" has no meaning in a foreign language.
NOT AVAILABLE"INNOVATIVE CELL THERAPIES"
Goods and ServicesScientific and technological services, namely, scientific and medical research and product development in the field of treatment, reconstruction, growth, renewal and repair of tissues and organs; medical research and consulting related thereto in the field of diagnostics and cell therapy and product research and development in the field of medical and surgical instruments

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, March 29, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNOVADIP BIOSCIENCES
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressBE
Party NameNOVADIP BIOSCIENCES
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBE
Party NameNOVADIP BIOSCIENCES
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBE

Trademark Events

Event DateEvent Description
Thursday, January 21, 2016SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, January 22, 2016LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, January 28, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 2, 2016APPLICATION FILING RECEIPT MAILED
Sunday, March 13, 2016ASSIGNED TO EXAMINER
Sunday, March 20, 2016NON-FINAL ACTION WRITTEN
Monday, March 21, 2016NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, March 21, 2016REFUSAL PROCESSED BY MPU
Monday, March 21, 2016NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, May 13, 2016REFUSAL PROCESSED BY IB
Tuesday, September 13, 2016TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, September 13, 2016ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, September 19, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, September 30, 2016ASSIGNED TO LIE
Thursday, October 6, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 6, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, November 14, 2016FINAL REFUSAL WRITTEN
Monday, November 14, 2016FINAL REFUSAL E-MAILED
Monday, November 14, 2016NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, May 10, 2017EXAMINERS AMENDMENT -WRITTEN
Wednesday, May 10, 2017EXAMINERS AMENDMENT E-MAILED
Wednesday, May 10, 2017NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, May 10, 2017EXAMINER'S AMENDMENT ENTERED
Wednesday, May 10, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, May 19, 2017LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, June 7, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 7, 2017NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, June 7, 2017NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Thursday, June 15, 2017CHANGE OF NAME/ADDRESS REC'D FROM IB
Wednesday, June 21, 2017NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Wednesday, June 21, 2017NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Friday, June 23, 2017NOTIFICATION PROCESSED BY IB
Tuesday, June 27, 2017PUBLISHED FOR OPPOSITION
Tuesday, June 27, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Saturday, July 8, 2017NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, September 12, 2017REGISTERED-PRINCIPAL REGISTER
Tuesday, December 12, 2017FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sunday, December 17, 2017FINAL DISPOSITION PROCESSED
Sunday, December 17, 2017FINAL DISPOSITION NOTICE SENT TO IB
Friday, January 26, 2018FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, May 24, 2019NEW REPRESENTATIVE AT IB RECEIVED
Saturday, March 20, 2021NEW REPRESENTATIVE AT IB RECEIVED
Monday, September 12, 2022COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, March 29, 2024CANCELLED SECTION 71
Saturday, November 30, 2024TOTAL INVALIDATION OF REG EXT PROTECTION CREATED

Related Keywords

therapies cell innovative novadip medical research field scientific product development thereto related consulting instruments